Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma

Background The phase 3 CheckMate 214 trial demonstrated higher response rates and improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line therapy for advanced clear-cell renal cell carcinoma (RCC). An unmet need exists to identify patients with RCC who are most likely...

Full description

Saved in:
Bibliographic Details
Main Authors: Jin Yao, Thomas Powles, David F McDermott, Toni K Choueiri, Petra Ross-MacDonald, Simon Papillon-Cavanagh, Robert J Motzer, M Brent McHenry, Megan Wind-Rotolo, Ron Ammar, Yann-Alexandre Vano, Saurabh Gupta, Celine Han, Shruti S Saggi
Format: Article
Language:English
Published: BMJ Publishing Group 2022-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/3/e004316.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/10/3/e004316.full

Similar Items